Chemist Schott Rocklage Managing Partner at 5AM Ventures
Scott Rocklage joined the company 5AM Ventures as a Venture Partner in back in 2003 and by 2004 he was a Managing Partner. Dr. Rocklage has spent over three decades overseeing various businesses in the healthcare management field of business and has strategic leadership qualities that led to the FDA approval of three (3) US New Drug Applications. In the past, Scott Rocklage has also served as Chairman of Cubist Pharmaceuticals and also has served as the CEO of Nycomed Salutar as well. Dr. Rocklage was also the Executive Chairman of the Ilypsa (acquired by Amgen) and Miikana (acquired by EntreMed).
Currently, Scott Rocklage serves as Board Chairman of Achaogen, Relypsa, and Semprus as well as a member of the board for WaverRx, Pulmatrix, and Variation as well as a member of the Board of Associates of the Whitehead Institute. Scott Rocklage also does his work with 5AM Ventures out of his offices while working from Boston, Massachusetts.
In addition to over 30 years of service in the healthcare management industry, Scott Rocklage has also pursued inventing things as well. Rocklage also has over 30 US patents and co-patents as an inventor. He has also appeared in more than 100 peer-reviewed publications throughout his career. Dr. Rocklage works from his offices based in Massachusetts and more information click here.
Dr. Scott Rocklage went to the University of California where he received a Bachelor of Science Degree in Chemistry. He moved on from there to MIT to get his PhD in Chemistry afterward. He conducted his research at the laboratory of Richard R. Schrock (Nobel Peace Prize of 2005) and learn more about Scott Rocklage.